84 related articles for article (PubMed ID: 26897090)
21. Triphenylphosphonium-linked derivative of hecogenin with enhanced antiproliferative activity: Design, synthesis, and biological evaluation.
Zhang J; Zhu W; Ma Y; Huang X; Su W; Sun Y; Liu Q; Ma T; Ma L; Sun J; Fan S; Wang X; Lin S; Wang W; Han C
Bioorg Chem; 2024 Apr; 145():107210. PubMed ID: 38364551
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer.
Wang Y; Wang C; Liu T; Qi H; Chen S; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
J Med Chem; 2024 Jan; 67(1):420-432. PubMed ID: 38146659
[TBL] [Abstract][Full Text] [Related]
23. Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKCθ inhibitors.
Katoh T; Takai T; Yukawa T; Tsukamoto T; Watanabe E; Mototani H; Arita T; Hayashi H; Nakagawa H; Klein MG; Zou H; Sang BC; Snell G; Nakada Y
Bioorg Med Chem; 2016 Jun; 24(11):2466-2475. PubMed ID: 27117263
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of diaminopyrimidine derivatives as novel focal adhesion kinase inhibitors.
Sun Y; Gao Z; Wang R; Zhang G; Wu T; Yin W; Sun Y; Qin Q; Zhao D; Cheng M
RSC Med Chem; 2023 Nov; 14(11):2301-2314. PubMed ID: 37974962
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, Biological Evaluation and Molecular Docking of Novel F-18-Labeled Focal Adhesion Kinase Inhibitors as Potential Tumor Radiotracers.
Yang H; Li Y; Liang H; Cui C; Gan L; Zhang H
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542861
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, and Biological Evaluation of 2-Substituted Aniline Pyrimidine Derivatives as Potent Dual Mer/c-Met Inhibitors.
Huang D; Chen Y; Yang J; Zhao B; Wang S; Chai T; Cui J; Zhou X; Shang Z
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257391
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
Li R; Gong L; Sun J; Liang Z; He J; Huang J; Ning X; Song H; Li R; Zhang Q; Lin Z; Yin Y
Bioorg Chem; 2024 Mar; 144():107134. PubMed ID: 38237389
[TBL] [Abstract][Full Text] [Related]
28. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments.
Lei H; Duan W; Zhang SQ; Feng Y; Ma M; Yuan B; Xin M
Bioorg Chem; 2023 Sep; 138():106594. PubMed ID: 37186998
[TBL] [Abstract][Full Text] [Related]
29. Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy.
Hu S; Jiang C; Jin Q
Eur J Med Chem; 2024 Apr; 269():116351. PubMed ID: 38547734
[TBL] [Abstract][Full Text] [Related]
30. Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.
Fang F; Dai Y; Wang H; Ji Y; Liang X; Peng X; Li J; Zhao Y; Li C; Wang D; Li Y; Zhang D; Zhang D; Geng M; Liu H; Ai J; Zhou Y
Acta Pharm Sin B; 2023 Dec; 13(12):4918-4933. PubMed ID: 38045061
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors.
Zhang H; Lin G; Jia S; Wu J; Zhang Y; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
Bioorg Chem; 2024 May; 148():107456. PubMed ID: 38761706
[TBL] [Abstract][Full Text] [Related]
32. Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy.
Lu D; Chen J; Qin L; Bijou I; Yi P; Li F; Song X; MacKenzie KR; Yu X; Yang B; Roy Chowdhury S; Korp JD; O'Malley BW; Lonard DM; Wang J
J Med Chem; 2024 Apr; 67(7):5333-5350. PubMed ID: 38551814
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Potent and Selective Phosphatidylinositol 3-Phosphate 5-Kinase (PIKfyve) Inhibitors as Methuosis Inducers.
Chen Y; Liu S; Wei Y; Wei H; Yuan X; Xiong B; Tang M; Yang T; Yang Z; Ye H; Yang J; Chen L
J Med Chem; 2024 Jan; 67(1):165-179. PubMed ID: 38117948
[TBL] [Abstract][Full Text] [Related]
34. Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of Malignancies.
Liu K; Yuan X; Yang T; Deng D; Chen Y; Tang M; Zhang C; Zou Y; Zhang S; Li D; Shi M; Guo Y; Zhou Y; Zhao M; Yang Z; Chen L
J Med Chem; 2024 Jan; 67(1):245-271. PubMed ID: 38117951
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent thiazolidin-4-one sulfone derivatives for inhibition of proliferation of osteosarcoma in vitro and in vivo.
Chen X; Luo Z; Hu Z; Sun D; He Y; Lu J; Chen L; Liu S
Eur J Med Chem; 2024 Feb; 266():116082. PubMed ID: 38232462
[TBL] [Abstract][Full Text] [Related]
36. Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents.
Wang Y; Nie G; Wang X; Ge W; Zhang Y
Bioorg Med Chem Lett; 2023 Nov; 96():129505. PubMed ID: 37838340
[TBL] [Abstract][Full Text] [Related]
37. Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability.
Xu J; Zhao A; Chen D; Wang J; Ma J; Qing L; Li Y; Fang H; He H; Pan W; Zhang S
Eur J Med Chem; 2024 Feb; 266():116160. PubMed ID: 38277917
[TBL] [Abstract][Full Text] [Related]
38. Defining the structure-activity relationship for a novel class of allosteric MKP5 inhibitors.
Gannam ZTK; Jamali H; Kweon OS; Herrington J; Shillingford SR; Papini C; Gentzel E; Lolis E; Bennett AM; Ellman JA; Anderson KS
Eur J Med Chem; 2022 Dec; 243():114712. PubMed ID: 36116232
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and biological evaluation of thiazole/thiadiazole carboxamide scaffold-based derivatives as potential c-Met kinase inhibitors for cancer treatment.
Nan X; Wang QX; Xing SJ; Liang ZG
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2247183. PubMed ID: 37642355
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies.
Danciu OC; Holdhoff M; Peterson RA; Fischer JH; Liu LC; Wang H; Venepalli NK; Chowdhery R; Nicholas MK; Russell MJ; Fan TM; Hergenrother PJ; Tarasow TM; Dudek AZ
Br J Cancer; 2023 Mar; 128(5):783-792. PubMed ID: 36470974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
